spacer
home > ict > spring 2006 > calling all innovators
PUBLICATIONS
International Clinical Trials

Calling all Innovators

Intelligent interpretation of regulations can breed confidence and bring innovation back to pharma, says Ian Leake of BearingPoint

The pharmaceutical industry is being challenged like never before. Increasing regulation, globalisation, and the neverending search for blockbusters have all contributed to spiralling costs. Yet greater public oversight of healthcare costs is making it harder for the industry to maintain its traditional profitability.

Industry executives have responded in several ways: consolidation (mergers and acquisitions), searching for lower cost locations (globalisation), and demands to make sweeping cuts to departmental budgets – in some cases as much as 30 per cent from year to year. But all of this activity requires flexibility and promotes change, and if there’s one thing that the industry has learnt over the years it’s that change invites risk. And this heavily regulated industry is extremely risk averse.

A major contributor to the risk averse culture in the industry is the traditional approach to regulatory compliance (socalled ‘old compliance’). Overlapping and sometimes conflicting global and local regulations, accepted and rarely challenged ‘best practices,’ and personal interpretations have created a complex and expensive web of policies and procedures that make change costly, painful, and tiresome. The biggest casualty of this has been innovation. In all areas of operation – from clinical trials to manufacturing to finance – it is just too hard to innovate: it’s easier and safer to just keep doing the same thing, even if it’s unsustainably slow and expensive.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ian Leake is a Senior Manager in BearingPoint’s Global Life Sciences Practice, and has 14 years’ experience in the pharmaceutical industry. He has extensive expertise in leading R&D, regulatory compliance and systems integration projects and programmes. Ian currently leads BearingPoint’s Regulatory Compliance Team in the UK.
spacer
Ian Leake
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Language Weaver now available for ServiceNow customers

RWS, the world’s leading provider of technology-enabled language, content management, and intellectual property services, has released a new Language Weaver Connector for ServiceNow
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement